NVAX SHAREHOLDERS- Possible Securities Fraud Violations by Novavax, Inc.: The Law Offices of Vincent Wong Investigate

October 22, 2021 4:48 PM EDT | Source: Vincent Wong Esq.

New York, New York--(Newsfile Corp. - October 22, 2021) - The Law Offices of Vincent Wong announce an investigation of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX) concerning possible violations of federal securities laws by certain officers and directors of the Company.

INVESTIGATION DETAILS: On October 19, 2021, Politico published an article titled, "'They Rushed the Process': Vaccine Maker's woes hamper global inoculation campaign," alleging manufacturing and purity problems in Novavax's process to produce Covid-19 vaccinations for COVAX, which is an international consortium working to provide two billion doses to middle- and low-income countries. Shortly after the article was published, the share price of Novavax fell over 20% in premarket trading.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7094/100612_7a19ca5fa4c4789c_001full_200.jpg

If you believe your NVAX investment was affected, contact us today:

https://www.wongesq.com/pslra-1/novavax-inc-loss-submission-form

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/100612

info